AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global $6.4 Bn Antacids Market 2020-2025 by Drug Class, Formulation, Distribution Channel, Geography and Impact of Covid-19 with Ansoff’s Analysis - ResearchAndMarkets.com

November 4, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Nov 4, 2020--

The “Global Antacids Market 2020-2025, by Drug Class, Formulation, Distribution Channel, Geography and Impact of Covid-19 with Ansoff’s Analysis” report has been added to ResearchAndMarkets.com’s offering.

ADVERTISEMENT

The Global Antacids Market is estimated to be USD 5.3 Bn in 2020 and is expected to reach USD 6.4 Bn by 2025 growing at a CAGR of 3.6%.

Antacids are usually over the counter (OTC) medications used in neutralizing the stomach acid. The market has seen wide availability of antacids in variety of forms. Manufacturers in the antacids market are approaching different drug formulation techniques to support flavoured, chewable tablets to capture the market.

Rising incidence of acidic refluxes like GERD, unhealthy lifestyle etc. have driven the growth of the market. However, the alternative market for antacids hinders the growth of this market.

Company Profiles

Some of the companies covered in this report are Pfizer, GlaxoSmithKline, Abbott India Private Ltd, Bayer AG, Takeda pharmaceuticals, Sun pharmaceuticals, Sanofi, Dr Reddy’s Laboratories etc.

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share etc.

Market Dynamics

Drivers

  • Increasing Prevalence of Gastro Esophageal Reflux Diseases (GERD)
  • Growing Geriatric Population
  • Increasing Prevalence Of Heartburn
  • Unhealthy lifestyle

Restraints

  • Growing number of alternatives in the market for antacids

Opportunities

  • Increasing awareness about GERD

Trends

  • Rise of E-commerce has augmented the demand for antacids
  • Melt in mouth antacid

ADVERTISEMENT

Key Topics Covered:

1 Report Description

1.1 Study Objectives

1.2 Market Definition

1.3 Currency

1.4 Years Considered

1.5 Language

1.6 Key Shareholders

2 Research Methodology

2.1 Research Process

2.2 Data Collection and Validation

2.3 Market Size Estimation

2.4 Assumptions of the Study

2.5 Limitations of the Study

3 Executive Summary

4 Market Overview

4.1 Introduction

4.2 Market Dynamics

4.2.1 Drivers

4.2.2 Restraints

4.2.3 Opportunities

4.3 Trends

5 Market Analysis

5.1 Porter’s Five Forces Analysis

5.2 Impact of COVID-19

5.3 Ansoff Matrix Analysis

6 Global Antacids Market, By Drug Class

6.1 Introduction

6.2 Proton Pump Inhibitor

6.3 H2 Antagonist

6.4 Acid Neutralizers

7 Global Antacids Market, By Formulation

7.1 Introduction

7.2 Tablet

7.3 Liquid

7.4 Powder

8 Global Antacids Market, By Distribution Channel

8.1 Introduction

8.2 Hospital Pharmacies

8.3 Retail Pharmacies

8.4 Online Pharmacies

9 Global Antacids Market, By Geography

10 Competitive Landscape

10.1 Competitive Quadrant

10.2 Market Share Analysis

10.3 Competitive Scenario

10.3.1 Mergers & Acquisitions

10.3.2 Agreements, Collaborations, & Partnerships

10.3.3 New Product Launches & Enhancements

10.3.4 Investments & Fundings

11 Company Profiles

11.1 Wellspring Pharm

11.2 Private Lable

11.3 Johnson & Johnson

11.4 Novartis Consumer Health

11.5 Boehringer Ingelheim Pharm

11.6 Glaxosmithkline

11.7 Procter & Gamble

11.8 First Aid Only

11.9 Pfizer

11.10 Bayer AG

11.11 Dr Reddy’s Laboratories

11.12 Reckitt Benckiser Group plc

11.13 Sanofi

11.14 Sun Pharmaceuticals

11.15 Takeda Pharmaceutical Company Limited

11.16 Abbott

12 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/ofnb5m

View source version on businesswire.com:https://www.businesswire.com/news/home/20201104005210/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 11/04/2020 04:32 AM/DISC: 11/04/2020 04:32 AM

http://www.businesswire.com/news/home/20201104005210/en